ArticleThe Journal of clinical endocrinology and metabolism2026

Ersodetug for refractory hypoglycemia due to malignant insulin-secreting tumors.

Jonathan Strosberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.